Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

983.26
-20.3100-2.02%
Pre-market: 978.36-4.9000-0.50%06:41 EST
Volume:3.77M
Turnover:3.70B
Market Cap:929.56B
PE:42.84
High:993.56
Open:990.00
Low:965.60
Close:1,003.57
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:1.22
T/O Rate:0.40%
Dividend:6.00
Dividend Rate:0.61%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:35.03
PE(LYR):42.84

Loading ...

Eli Lilly announces long-term data on Omvoh in Crohn’s disease

TIPRANKS
·
Feb 20

Lilly Says Omvoh Maintains Steroid-Free Remission for Three Years in Crohn’s Disease Patients

Reuters
·
Feb 20

Eli Lilly - Over 90% Maintained Steroid-Free Control Through Three Years

THOMSON REUTERS
·
Feb 20

Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial

TIPRANKS
·
Feb 20

Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating

MT Newswires Live
·
Feb 19

Three multinationals pay almost half of all Irish corporate tax, watchdog says

Reuters
·
Feb 19

U.S. RESEARCH ROUNDUP-EBay, Huntsman, Palo Alto

Reuters
·
Feb 19

Eli Lilly : Berenberg Raises Target Price to $1050 From $950

THOMSON REUTERS
·
Feb 19

Eli Lilly Stock (LLY) in Focus as Zepbound Found to Help Treat Psoriasis

TIPRANKS
·
Feb 18

BRIEF-Lilly's Taltz (Ixekizumab) And Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy In First-Of-Its-Kind Phase 3B Trial

Reuters
·
Feb 18

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Reuters
·
Feb 18

Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy in First-of-Its-Kind Phase 3B Trial for Adults With Psoriasis and Obesity or Overweight

THOMSON REUTERS
·
Feb 18

Eli Lilly: Taltz, Zepbound Met Primary Endpoint of Superiority VS. Taltz Monotherapy in Achieving Complete Skin Clearance, ≥10% Weight Loss

THOMSON REUTERS
·
Feb 18

Eli Lilly: at 36 Weeks, Treatment With Taltz, Zepbound Met Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Feb 18

Eli Lilly: in Secondary Endpoint, Patients Taking Taltz, Zepbound Were 40% More Likely to Achieve Pasi 100 Compared to Those Taking Taltz Alone

THOMSON REUTERS
·
Feb 18

Daiwa Securities Adjusts Price Target on Eli Lilly to $1,250 From $1,230, Maintains Buy Rating

MT Newswires Live
·
Feb 18

BUZZ-Australia's CSL recovers after signing licensing deal with Eli Lilly

Reuters
·
Feb 18

BRIEF-CSL And Lilly Enter Licensing Agreement For Clazakizumab

Reuters
·
Feb 18

Eli Lilly Stock (LLY) Rises on Plan to Invest $1 Billion in India

TIPRANKS
·
Feb 18

Lilly targets India as global export hub amid booming Mounjaro sales, executive says

Reuters
·
Feb 17